Skip to main content
. 2022 Apr 27;11(9):1478. doi: 10.3390/cells11091478

Figure 11.

Figure 11

HSP90 inhibition reduces T2R-stimulated pHrodo-S. aureus phagocytic responses in primary human M0 MΦs. (A): Representative images of pHrodo-labeled S. aureus phagocytosis in primary human MΦs ± denatonium benzoate (1 mM) stimulation after D-NAME or L-NAME pretreatment (10 µM; 45 min). (B): Bar graph of pHrodo-S. aureus fluorescence after experiments as in A. Significance by Bonferroni post-test with paired comparisons; ** p < 0.01. (C): Representative images of pHrodo-labeled S. aureus phagocytosis in primary human MΦs ± denatonium benzoate (1 mM) or 3oxoC12HSL (100 µM) after no-pretreatment (0.1% DMSO only as vehicle control)) or pretreatment with HSP90 inhibitors geldanamycin or BIIB 021 (pretreatment as in Figure 8). (D): Bar graph of pHrodo-S. aureus phagocytosis during stimulation with HBSS only (unstimulated control), 1 mM denatonium benzoate, or 100 µM 3oxoC12HSL ± geldanamycin or BIIB 021 (pretreatment as in Figure 9). Significance by one-way ANOVA with Bonferroni post-test; * p < 0.05 or ** p < 0.01. (E): Bar graph of pHrodo-S. aureus phagocytosis during stimulation with HBSS only (unstimulated control) or 1 mM denatonium benzoate ± pertussis toxin (PTX), geldanamycin, BIIB 021, 17-AAG, or VER 15508. PTX (500 ng/mL) pretreatment was 18 h. MΦs were pretreated with other inhibitors as in Figure 9. Significance by one-way ANOVA with Bonferroni post-test; ** p < 0.01.